News

Infectious Disease Advisor21h
Ready-To-Use, Low IgA Gammagard Liquid ERC Approved for Primary Immunodeficiency
The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.
Dermatology Advisor21h
Benlysta Autoinjector Approved for Pediatric Patients with Lupus Nephritis
The FDA has approved Benlysta for SC administration using an autoinjector in patients 5 years of age and older with active LN.
Clinical Advisor21h
FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations
In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.